Informace o publikaci

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

Autoři	FIEGL M. STAUDER R. STEURER M. MIAN M. HOPFINGER G. BRYCHTOVÁ Yvona SKRABS C. ZABERNIGG A. SCHMID F. HASLBAUR F. WINDER G. WALDER A. LANG A. VOSKOVA D. GREIL R. MAYER Jiří GASTL G.
Rok publikování	2014
Druh	Článek v odborném periodiku
Časopis / Zdroj	Annals of Hematology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1007/s00277-013-1966-z
Obor	Onkologie a hematologie
Klíčová slova	Chronic lymphocytic leukemia; CLL ; Alemtuzumab; B-cell prolymphocytic leukemia; B-PLL; Observational study
Popis	This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced B-cell chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (B-PLL) to definitely describe the impact of this antibody in clinical routine use. Data were collected from 208 consecutive, mainly pretreated, patients with CLL (n=202), and B-PLL (n=6) who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) in various settings were assessed,and toxicities were documented. In these routine patients, a comparably low cumulative dose of alemtuzumab (median,403 mg) was applied. In CLL, overall response rate was 32%, and various pre-therapeutic parameters were predictive for inferior response, among them, the prior administration of >/- 3 therapy lines (P<0.001), refractoriness to fludarabine (P=0.002), and bulky lymphadenopathy (P=0.003). PFS and OS after start of alemtuzumab were 6.2 and 21.0 months, respectively. Bulky lymphadenopathy was the prominent risk factor for both inferior PFS (P<0.001) and OS (P=0.002). In BPLL,four patients experienced a fatal outcome, whereas two patients had some benefit with alemtuzumab. The main adverse effects were CMV reactivation (20%) and a broad spectrum of infections, which together were the main reasons for treatment interruption and/or premature termination. In conclusion, alemtuzumab administered even at low dose levels was effective but overall considerably toxic in routine CLL patients. We emphasize that alemtuzumab remains an important therapeutic option in subsets of CLL patients.